Patient Access program for Infacort and Chronocort to launch in Europe

UK specialty pharma firm Diurnal Group (AIM: DNL) has entered into a partnership with Clinigen Group’s (AIM: CLIN) IDIS Managed Access division to launch a Patient Access program in Europe for the company’s lead products, Infacort and Chronocort, for patients with diseases of cortisol deficiency.

The Patient Access program will enable physicians in Europe to prescribe Infacort and Chronocort as unlicensed medicines on a named patient basis for patients who have no other treatment options, ahead of anticipated European approval and commercial launch of the products.

Infacort is a preparation of hydrocortisone (the synthetic version of cortisol) specifically designed for use in children suffering from adrenal insufficiency (AI), including the related disease, congenital adrenal hyperplasia (CAH). Chronocort is a modified-release hydrocortisone preparation that has been designed to mimic the natural circadian rhythm of cortisol when given in a twice-a-day “toothbrush” regimen for the treatment of adult CAH.